PolyPid PYPD 深 沪
等待开盘 10-23 09:30:00 美东时间
5.155
+0.085
+1.68%
华盛通- 最 高5.19
- 今 开5.02
- 成交量 13.16万股
- 最 低 4.92
- 昨 收 5.07
- 总市值 1.05亿
- 52周最高 5.73
- 市盈率 静 --
- 换手率 0.65%
- 52周最低 3.50
- 委 比 24.53%
- 总股本 2031.18万
- 历史最高 583.50
- 量 比 2.03
- 振 幅 5.33%
- 历史最低 2.30
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PolyPid收涨3.39%，成交额54.46万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-20 07:08
PolyPid收跌3.67%，成交额72.04万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:08
PolyPid’s D-PLEX₁₀₀ Application Validated by EMA, Advancing Dual EU–U.S. Reviews
PolyPid ( ($PYPD) ) has shared an announcement. PolyPid announced on October 1,...
10-01 21:48
PolyPid Agrees With ADVANZ PHARMA To Terminate Their 2022 Exclusive License, Distribution And Supply Agreement For D-PLEX₁₀₀ In Europe
As a result, the exclusive European commercialization rights for D-PLEX₁₀₀ have reverted to PolyPid.
10-01 21:11
Analysts Are Bullish on These Healthcare Stocks: PolyPid (PYPD), Equillium (EQ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-14 10:30
PolyPid (PYPD) 2026年第二季度业绩电话会议：D-PLEX100优先审评与Azurity交易
PolyPid 2026财年第二季度业绩电话会议涵盖了D-PLEX100优先审评、11月PDUFA日期、与Azurity的交易、净亏损收窄以及可支撑至2028年的现金储备。
08-14 08:35
PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 55.13 percent increase over losses of $(0.78) per share from the same period last year.
08-12 19:30
PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28
The FDA did not identify any filing review issues and set a Prescription Drug User Fee Act ("PDUFA") target action date of November 28, 2026, approximately one quarter ahead of the Company’s previously communicated first quarter 2027 guidance. Priority Review shortens the FDA’s target review timelin...
07-29 20:34
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the "Agreement") with Azurity Pharmaceutic...
07-21 19:32
